BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

COREE Identifies First-Ever Microbiome Biomarkers for Diabetes and Obesity Patients

COREE announced on September 15 that it had, for the first time in the world, identified microbiome biomarkers specific to diabetes and obesity p...

September 29, 2025 | News

The $100 Billion Question: Can India Lead the Global Diabetes Economy?

India’s Diabetes Burden and Global Stakes: India is often called the “diabetes capital of the world,” and not without reason. Recent esti...

September 24, 2025 | Analysis | By editor@biopharmaapac.com

China’s NMPA Approves Innovent’s Mazdutide, the World’s First Dual GCG/GLP-1 Receptor Agonist for Type 2 Diabetes

Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatm...

September 22, 2025 | News

Could Early Lifestyle Interventions Change the Course of Type 2 Diabetes?

According to the Centers for Disease Control and Prevention (CDC), over 38 million Americans have diabetes. Of these, around 90% to 95% have Type 2 diabete...

September 18, 2025 | News

Roche Expands AI-Enabled Accu-Chek SmartGuide CGM with mySugr App Integration Across Europe, Latin America and Asia-Pacific

The integration of Accu-Chek SmartGuide's AI-enabled predictive CGM with the popular mySugr app delivers a simple, intuitive solution...

September 17, 2025 | News

Rona Therapeutics Submits RN3161 to Australian HREC as INHBE-Targeting GalNAc siRNA for Obesity

Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, announced the successful submission of RN3161 to the Australian Human R...

September 16, 2025 | News

China Grants First Approval for Tzield to Delay Onset of Type 1 Diabetes

Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight year...

September 11, 2025 | News

China’s Bon Natural Life Unveils Tea-Derived Compounds for Weight Management Through AI-Powered Drug Discovery

Bon Natural Life Limited , a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking identif...

September 03, 2025 | News

Wegovy® Demonstrates Superior Cardiovascular Benefit Over Tirzepatide in Real-World Study

Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart atta...

September 01, 2025 | News

Ascletis Reports 44.8% Weight Reduction in Obese Mouse Model with Combination of ASC47 and Novel Dual GLP-1R/GIPR Agonist ASC31

Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), ...

August 19, 2025 | News

Novo Nordisk Expands U.S. Access to FDA-Approved Ozempic® with $499 Monthly Offer for Uninsured Patients

Offer supports access for eligible patients without insurance to FDA-approved Ozempic® (semaglutide) injection 0.5 mg, 1 mg,...

August 19, 2025 | News

Superluminal Medicines and Eli Lilly Forge $1.3 Billion Collaboration on Undisclosed GPCR Targets in Cardiometabolic Disease and Obesity

Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as...

August 15, 2025 | News

Innovent Biologics gets FDA nod to begin Phase 1 trials of oral GLP-1R agonist IBI3032

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

August 05, 2025 | News

Fangzhou and Novo Nordisk Forge Strategic Alliance to Revolutionise Chronic Disease Management with AI

Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, ...

July 21, 2025 | News

Stay Connected